Financial Contrast: Kyverna Therapeutics (NASDAQ:KYTX) vs. Tourmaline Bio (NASDAQ:TRML)

Tourmaline Bio (NASDAQ:TRML) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Institutional and Insider Ownership

91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Tourmaline Bio and Kyverna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tourmaline Bio	N/A	-19.50%	-19.04%
Kyverna Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Tourmaline Bio and Kyverna Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tourmaline Bio	N/A	N/A	-$42.12 million	($6.50)	-2.36
Kyverna Therapeutics	$7.03 million	45.02	-$60.37 million	N/A	N/A

Tourmaline Bio has higher earnings, but lower revenue than Kyverna Therapeutics.

Analyst Ratings

This is a summary of recent ratings and target prices for Tourmaline Bio and Kyverna Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tourmaline Bio	0	0	6	0	3.00
Kyverna Therapeutics	0	1	5	0	2.83

Tourmaline Bio currently has a consensus price target of $61.80, suggesting a potential upside of 302.61%. Kyverna Therapeutics has a consensus price target of $34.40, suggesting a potential upside of 368.66%. Given Kyverna Therapeutics’ higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Tourmaline Bio.

Summary

Tourmaline Bio beats Kyverna Therapeutics on 5 of the 9 factors compared between the two stocks.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.